SUBANG JAYA, Malaysia, June 23, 2025 /PRNewswire/ -- Taylor's University has secured the 253^rd position in the latest QS World University Rankings 2026, reinforcing its status as the top-ranked non-government-linked private university in Southeast Asia. This achievement marks Taylor's consistent presence in the top 1% of universities worldwide.

Taylor's strong global standing is underscored by its 92^nd ranking for employer reputation, making it the top private institution in Southeast Asia for this indicator. This aligns with findings from the Ministry of Higher Education's (MOHE) 2024 Graduate Tracer Study, which reports a 99.5% graduate employability rate for Taylor's—well above the national average of 92.5%. This indicator highlight that Taylor's graduates are highly sought after for their industry-relevant skills and readiness to contribute effectively in the workforce.

Equally important is Taylor's commitment to nurturing a globally diverse student community, as demonstrated by its 34^th ranking for international student population, reflecting the university's success in attracting and supporting a vibrant, globally minded student body.

"As a modern progressive institution, we are committed to building world-class education driven by innovation and real-world impact. We are growing our student community, investing in staff, and advancing capabilities to address global challenges through industry partnerships, AI-powered learning, and purpose-driven innovation. In line with our aspirations to facilitate nation-building efforts, we aim to empower students to reach their full potential, align research with national priorities, and foster local and global partnerships that drive meaningful change. In doing so, we support Malaysia's efforts to develop talent and strengthen its position as an education hub in the region," said Professor Barry Winn, Vice-Chancellor and President of Taylor's University.

Taylor's University is committed to advancing purpose-driven education, reinforcing academic integrity across borders amid the rise of transnational education, and reimagining curricula to reflect diverse, globally relevant, and locally grounded perspectives. At the same time, the university is redefining faculty roles—empowering educators as mentors, innovators, and change agents—to deliver dynamic hybrid learning experiences that equip graduates to navigate the complexities of the future.

For more information about Taylor's University and its programmes, please visit the website.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/taylors-university-continues-strong-global-performance-in-qs-world-university-rankings-2026-302487817.html

SOURCE Taylor's University

SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025) (hereinafter referred to as the "Specifications") have been officially published in the Chinese Journal of Laboratory Medicine. The Specifications aim to offer standardized protocols for microbiology laboratory professionals and clinicians to conduct and interpret in vitro antimicrobial susceptibility testing (AST) of eravacycline. It supports rational clinical use of eravacycline based on standardized evidence and enhances the accuracy and consistency of susceptibility testing results across clinical microbiology laboratories, thereby better addressing the challenges of treating multidrug-resistant (MDR) and complicated infections.

The Specifications were jointly developed by the Expert Committee of the National Health Commission on Antimicrobial Susceptibility Testing and Standard Research (hereinafter referred to as the "ChinaCAST"), the Clinical Microbiology Laboratory Specialized Committee of Chinese Hospital Association, and the Chinese Committee on Antimicrobial Susceptibility Testing, affiliated to the European Committee on Antimicrobial Susceptibility Testing (EUCAST).

As a novel fluorocycline antimicrobial, eravacycline possesses broad-spectrum antibacterial coverage, potent activity, and favorable safety and efficacy in comparison to a carbapenem in the registrational trials. It is widely applied in the treatment of multidrug-resistant (MDR) pathogens and complicated intra-abdominal infections. The Specifications comprehensively outline three key areas: the antimicrobial mechanism and features of eravacycline, the AST methods, and clinical breakpoints for result interpretation. It emphasizes the standardization of procedures and accuracy of interpretation, and covers leading AST methodologies including broth microdilution, gradient diffusion (MTS/Etest), and disk diffusion methods, along with defined quality control parameters and interpretive criteria.

This publication complements the China clinical breakpoints for eravacycline released by ChinaCAST in 2024, creating a unified technical framework that integrates breakpoint definitions with standardized testing protocols. These breakpoints were established based on thorough evaluation of international standards, including those from EUCAST and the FDA, and were further informed by the latest in vitro and clinical research data from China and other global regions. The clinical breakpoints include minimum inhibitory concentration (MIC) and zone diameter criteria for common pathogens such as Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus anginosus group, Bacteroides fragilis, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. Eravacycline is the first and currently the only antimicrobial agent to have been granted China-specific clinical breakpoints following formal expert evaluation by ChinaCAST. This publication and the granting of China's clinical breakpoints for eravacycline mark a milestone in establishing China's national antimicrobial susceptibility standards.

"The publication of Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025) in the Chinese Journal of Laboratory Medicine marks a pivotal transition for China's antimicrobial susceptibility testing standards from adopting international references to independent formulation, " said Professor Yingchun Xu, The inaugural chairman of the Chinese Committee of the EUCAST (European Committee on Antimicrobial Susceptibility Testing) and Chair of the Department of Clinical Laboratory Diagnostics, Peking Union Medical College. "The establishment of clinical breakpoints for eravacycline, a novel drug approved by China's NMPA, will ensure procedural standardization and result accuracy of Antimicrobial Susceptibility Testing of eravacycline in clinical laboratories, achieving 'standardization and uniformity.' This advancement will guide rational clinical use of new antimicrobial agents, expand treatment options, and improve patient prognoses, while significantly contributing to Combating Bacterial Resistance. According to the final report of the "Comprehensive Evaluation Project on the Clinical Application of Eravacycline.", released by the National Health Commission of China, the efficacy of eravacycline in treating drug-resistant bacterial infections, especially in ICU and hematology applications, has brought significant clinical benefits to patients."

"Currently, antimicrobial resistance has been listed by the World Health Organization as one of the top ten public health threats globally, bringing a heavy disease burden to human health. The official publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025) marks a critical step toward the standardized clinical application of XERAVA^® (eravacycline)." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "The Specifications provides clinical microbiology laboratories with a standardized procedural pathways and evidence-based practice guideline, helping to enhance the consistency of susceptibility testing procedures and the accuracy of result reporting. This will enable more patients threatened by drug-resistant infections to benefit from eravacycline-based therapies. Furthermore, it establishes a robust foundation for ensuring the rational clinical use of XERAVA^® in the treatment of complicated infections thereby facilitating its inclusion in clinical pathways and treatment guidelines to maximize its value in combating resistant bacterial infections. As the first and only flourocycline antibiotic, eravacycline has been recommended by multiple domestic and international treatment guidelines. It is also included in the WHO's updated 2024 list of antimicrobials of high medical importance."

The Comprehensive Evaluation Project, led by the National Health Commission's Expert Committee on Clinical Use of Antimicrobials and Evaluation of Antimicrobial Resistance,  began in September 2023, and the data analysis was completed in November 2024. A total of 3,369 cases from 839 physicians across 231 hospitals nationwide were collected. Six final reports were released, including one overall project data analysis report and five specialty reports. The final report showed a 91.1% overall efficacy rate after 3 days of eravacycline treatment, and the 90.1% at the end of treatment.

In March 2024, the World Health Organization (WHO) updated its list of "Medically Important Antimicrobials" (MIA). Based on the novel modification of the tetracycline side chain, which significantly changes its resistance mechanisms, the WHO categorized fluorocycline as a new class of antimicrobial drugs, with eravacycline as the only drug in this class.

XERAVA^® was approved by the National Medical Products Administration (NMPA) of China in March 2023 and commercially launched in July. Its antibacterial spectrum covers a wide range of clinically relevant bacteria, including Gram-negative, Gram-positive, anaerobic bacteria. Eravacycline has been included in several clinical guidelines and expert consensuses, such as the 2023 edition of China's "Diagnosis, Treatment, and Prevention Guidelines for Carbapenem-Resistant Gram-Negative Organisms (CRO) Infections".

About XERAVA^® (eravacycline)

XERAVA^® (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative, Gram-positive and anaerobic pathogens, including those pathogens that have acquired multidrug resistance (MDR) and are prevalent in China. XERAVA^® is currently approved for the treatment of complicated intra-abdominal infections (cIAI) in the US, EU, UK, Singapore, mainland China, Hong Kong, and Taiwan. XERAVA^® was licensed to Everest by Tetraphase Pharmaceuticals, Inc., an affiliate of Innoviva Specialty Therapeutics, Inc.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

View original content:https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-official-publication-of-the-specifications-for-antimicrobial-susceptibility-testing-of-eravacycline-2025-302487762.html

SOURCE Everest Medicines

MELBOURNE, Australia, June 23, 2025 /PRNewswire/ -- SSAB has taken decisive action against two Indian companies selling counterfeit steel. The unauthorised products, labelled with the Hardox^® trademark, exhibited severe quality issues, posing risks to buyers who believed they were purchasing genuine Hardox^® wear plate.

Following a recent investigation and lawsuit in India, two companies based in the Mumbai area admitted to trademark infringement and passing off, both serious violations of SSAB's intellectual property rights. The companies not only paid exemplary damages but also faced a permanent injunction in the lawsuit and were directed to cease all use of the infringing marks. Additionally, they issued unconditional public apologies to SSAB.

Protecting customers from counterfeit products in Australia 

Only the Swedish steel manufacturer SSAB produces genuine Hardox^® wear plate, and Hardox^® wear plate is only available from SSAB and from SSAB-certified suppliers. Each month, SSAB successfully removes hundreds of website links, online marketplace advertisements and social media pages based in India and China, offering counterfeit products or falsely claiming to stock genuine Hardox^® wear plate for export to Australia and other parts of the world, often at very low prices.

Hardox^® wear plate is a premium, high-quality product known for its exceptional hardness and toughness. Its guaranteed properties deliver outstanding performance, making it a market leader in wear resistance—and naturally, not a low-cost option. Therefore, a simple guiding principle is that if a deal seems too good to be true, it likely involves counterfeit steel. SSAB strongly encourages buyers to purchase Hardox^® wear plate only from SSAB-certified suppliers.

Where to buy genuine Hardox^® wear plate and wear parts in Australia

SSAB maintains its own sales network. To ensure product authenticity, Hardox^® wear plate should only be purchased through SSAB's own local stocks in Australia, SSAB's mills and through our authorised Hardox^® Wearparts Centers in the Pacific region. https://www.hardoxwearparts.com/find-center/

Reporting counterfeit steel

At SSAB, we are committed to ensuring that customers receive only high-quality, genuine Hardox® wear plate they can trust. If you encounter branded steel that you suspect is not genuine Hardox® wear plate, we urge you to contact your local SSAB sales team immediately.

The risks of buying from unauthorized sources

Buying from unauthorised sources may result in:

• Operational setbacks – Counterfeit steel often has lower quality and therefore lower durability, leading to frequent repairs, replacements and increased maintenance costs.
• Health and safety risks – Inferior materials may compromise structural integrity, increasing the risk of failures and accidents.
• Legal repercussions – The use of counterfeit steel could lead to litigation, fines or other regulatory consequences.
• Environmental impact – Counterfeit production methods often neglect sustainability standards, leading to increased contamination and waste.

SSAB is a Nordic and US-based steel company that builds a stronger, lighter and more sustainable world through value added steel products and services. Working with our partners, SSAB has developed SSAB Fossil-free™ steel and plans to reinvent the value chain from the mine to the end customer, largely eliminating carbon dioxide emissions from our own operations. SSAB Zero™, a largely carbon emission-free steel based on recycled steel, further strengthens SSAB's leadership position and our comprehensive, sustainable offering independent of the raw material. SSAB has employees in over 50 countries and production facilities in Sweden, Finland and the US. SSAB is listed on Nasdaq Stockholm and has a secondary listing on Nasdaq Helsinki. Join us on our journey! www.ssab.com, Facebook, Instagram, LinkedIn, X and YouTube.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/steelmaker-ssab-the-manufacturer-of-hardox-wear-plate-cracks-down-on-counterfeit-goods-302484857.html

SOURCE SSAB

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are associated with significantly accelerated biological ageing and a more than threefold increase in the risk of premature death. This study is the first to show that nightmares independently predict faster biological ageing and earlier mortality – even after accounting for other health issues. 

Led by Dr Abidemi Otaiku of the UK Dementia Research Institute and Imperial College London, the study analysed data from 2,429 children aged 8 to 10 and 183,012 adults aged 26 to 86 across six long-term population cohorts.

Nightmare frequency in adults was self-reported at the start of the study, with participants followed for up to 19 years. For children, nightmare frequency was reported by their parents at the beginning of the study.

Results showed that adults reporting weekly nightmares were more than three times as likely to die prematurely (before age 70) compared to those who rarely or never experienced nightmares. Children and adults with more frequent nightmares also exhibited faster biological ageing, which accounted for approximately 40% of the heightened mortality risk.

Notably, weekly nightmares were found to be a stronger predictor of premature death than other established risk factors such as smoking, obesity, poor diet, and low physical activity. 

"Our sleeping brains cannot distinguish dreams from reality", Dr Otaiku explained. "That's why nightmares often wake us up sweating, gasping for breath, and with our hearts pounding – because our fight-or-flight response has been triggered. This stress reaction can be even more intense than anything we experience while awake." 

He continued, "Nightmares lead to prolonged elevations of cortisol, a stress hormone closely linked to faster cellular ageing. For those who frequently experience nightmares, this cumulative stress may significantly impact the ageing process. Additionally, nightmares disrupt both sleep quality and duration, impairing the body's essential overnight cellular restoration and repair. The combined effects of chronic stress and disrupted sleep likely contribute to the accelerated ageing of our cells and bodies."

The association between frequent nightmares and accelerated ageing remained consistent across all ages, sexes, ethnicities, and mental health statuses, indicating a universal effect. Even monthly nightmares were linked to faster ageing and increased mortality compared to rare or no nightmares, emphasising the importance of reducing nightmare frequency across the population.

SOURCE European Academy of Neurology (EAN) Congress

SEOUL, South Korea, June 23, 2025 /PRNewswire/ -- Novogene, a global leader in next-generation sequencing (NGS) and multi-omics solutions, today announced the establishment of Novogene Korea Limited, a wholly owned subsidiary headquartered in Seoul. This strategic expansion deepens Novogene's long-standing engagement with Korea's biomedical and biotech sectors, reinforcing its commitment to delivering rapid, high-quality, and cost-effective multi-omics services tailored to local research needs.

The new entity provides localized customer support, shorter project timelines, and stronger collaboration with Korea's vibrant scientific community — spanning cancer genomics, microbiome studies, precision medicine, and agricultural genomics. Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond.

"South Korea is a global innovation hub, and by establishing a dedicated team in Seoul, we are investing in the future of multi-omics discovery," said Justin Lee, Vice President, Novogene Asia Pacific, Middle East & Africa (AMEA). "With the launch of Novogene Korea, we are even better positioned to support our customers with rapid, cost-effective, and reliable services that are already trusted by more than 7,300 organizations worldwide. We sincerely thank the Korean scientific community for their continued trust and collaboration in advancing the frontiers of science."

Backed by robust government R&D support, world-class academic institutions, and a dynamic biotech ecosystem, South Korea is uniquely positioned to lead the next wave of genomic innovation. Novogene Korea will partner closely with universities, start-ups, and research hospitals to help unlock transformative insights in health, agriculture, and beyond.

About Novogene

Novogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation.

For more information, visit novogene.com/kr

Media Contact: Novogene AMEA (APAC, Middle-East & Africa), marketing_amea@novogeneait.sg 

View original content:https://www.prnewswire.com/apac/news-releases/novogene-establishes-new-subsidiary-in-korea-to-accelerate-multi-omics-research-302486871.html

SOURCE Novogene

SYDNEY, June 23, 2025 /PRNewswire/ -- Kaneka Corporation Supplement Division APAC, the world-renowned manufacturer and global supplier of Ubiquinol is thrilled to announce that Kaneka Ubiquinol™ has been awarded the prestigious Forbes Packaging Marketing Award 2025 at the Natural Health Products New Zealand (NHPNZ) Summit, further elevating the brand's position and stature in the natural health industry across the APAC region.

The win reflects Kaneka Ubiquinol's outstanding efforts in shining the spotlight on the role of mitochondrial health powered by Ubiquinol, in supporting optimal wellbeing. The award celebrates the strategic impact, scientific credibility and executional excellence of its multi-channel marketing programs which have worked to reach, engage and build trust with brandholders, healthcare professionals, pharmacists, media and consumers alike. As a result this has helped position mitochondrial health and Ubiquinol as the new frontier of evidence-based wellbeing.

Mitochondria, powered by the naturally occurring antioxidant ubiquinol, are the millions of "powerhouses" found in all cells that generate energy in our body. They are found in the largest concentrations in tissues and organs requiring the highest levels of energy production – heart, brain, liver, lungs, muscles, sperm and ovum. Science shows that from the age of approximately 30 + natural Ubiquinol levels start to decline, which may require supplementation.

Kaneka Ubiquinol's unique globally patented precision yeast fermentation process enables the production of bioidentical Ubiquinol, delivering a premium, clinically proven ingredient that supports mitochondrial health.

Upon receiving the award Tsuyoshi Takakuwa, Head of Marketing & Sales (APAC) Supplemental Nutrition Business Division, Kaneka Corporation, Japan said "this recognition reflects the collective efforts of our marketing, science, R&D teams, healthcare practitioner partners, brandholders, KOLs and, importantly consumers, united by a shared commitment to science, quality, education and a long-term vision to cement Ubiquinol's role as the foundation of mitochondrial health." 

On congratulating the team, Kazuki Takita, Oceania & Asia Marketing & Sales Team, Supplement Business Group, Supplement Strategic Unit, added that the award is a powerful testament of the success of the brand's multi-market, multi-channel strategy, which supports Kaneka Ubiquinol's presence and credibility across the APAC region.

"This award illustrates our strategic vision: to position Kaneka Ubiquinol™ as a trusted ingredient for healthcare professionals, a premium asset for brandholders, and a clinically supported ingredient for consumers seeking high-quality, evidence-based supplementation to support their overall health and wellbeing," he continued.

"Thank you to NHPNZ and the judging panel for this honour and we extend our congratulations to all the other finalists and winners."

ABOUT KANEKA UBIQUINOL™

Kaneka Ubiquinol™ is supported by 100+ scientific studies, 80+ patents and 45+ years of research, with applications spanning mitochondrial health, cardiovascular health, cognitive function, women's health, reproductive health, energy production, sleep, stress, healthy ageing and vitality.

Kaneka Ubiquinol's impeccable standards are built on the Japanese philosophy of 'Kaizen' meaning 'a commitment to quality, efficiency and pursuit of perfection', from the company's rigorous commitment to quality and research, to their outstanding stakeholder support. Its strict adherence to the highest manufacturing standards guarantees a stable ingredient, free from impurities, meeting rigorous standards and sustainability requirements, setting the global benchmark for production quality. Listed in over 50 countries in 1000+ practitioner and OTC nutraceutical brands since 2006.

Kaneka Ubiquinol™ is the proud winner of multiple awards including:

• Natural Health Products New Zealand Marketing Award 2025
• Complementary Medicines Australia Raw Material Supplier of the Year Award 2024
• Nutraingredients-Asia Healthy Ageing Ingredient of the Year Award 2024
• FFWS Ingredient Award - Cardiovascular Health Award 2024
• FFWS Ingredient Award - Healthy Ageing 2025

www.ubiquinol.net.au 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/kaneka-ubiquinol-wins-coveted-marketing-award-2025-at-natural-health-products-new-zealand-summit-302486940.html

SOURCE Kaneka Corporation Supplement Division APAC

GUANGZHOU , June 22, 2025 /PRNewswire/ -- In the fiercely competitive FMCG market, only efficient innovation can create a true competitive edge. As consumer preferences change rapidly and the market environment remains uncertain, how can companies precisely identify needs, execute efficiently, and continuously optimize their strategies?

The Cyberway Product Innovation Platform empowers FMCG enterprises to achieve sustainable growth by providing powerful capabilities in pre-planning insight, in-process control, and post-launch analytics—ultimately enabling the development of exceptional product strength.

Before: AI-Powered Foresight for Accurate Market Opportunity Detection

• AI Opportunity Discovery: Real-time industry data, user behavior, and competitor insights are captured to automatically identify blue ocean markets and unmet needs—fueling inspiration for new product planning.

Accelerate Opportunity Capture: Shorten market research cycles and improve speed and accuracy of opportunity identification.

• AI-Driven Product Definition: Using opportunity and competitor analysis, combined with internal product knowledge bases, the system intelligently generates product concepts, optimizes configurations, and refines packaging and formulas.

Agile Response: Ensure product design closely aligns with market needs and competition, allowing rapid focus on core value and improving product-market fit.

• End-to-End User Demand Management: A comprehensive demand management framework tracks records, statuses, and feedback, aggregating omnichannel voice of customer with AI to identify high-value needs.
  Efficient & Accurate: By realizing and verifying demand in closed-loop cycles, continuously refine product performance, minimize resource waste, and pave the way for the next breakout product.

During: Efficient Execution to Deliver Outstanding Products

• Scientific Project Management System: Integrates visual dashboards, all-in-one workbenches, and real-time notifications via Feishu, WeCom, and DingTalk for full project transparency and synchronized decision-making across teams.

Core Value: Reduce communication overhead, improve collaboration efficiency, and prevent project delays.

• Standardized Project Workflow: Based on industry templates and task libraries, enabling tiered and structured project management tailored to channel requirements.

Flexible Control: Guarantees high-quality delivery while allowing adaptive workflows, ensuring key tasks succeed the first time.

• Cross-Functional Online Collaboration: Integrates marketing, go-to-market, and product workflows to shorten timelines. Interlocked nodes require mutual confirmation to ensure stability and avoid cost waste.

Key Feature: Enables synergistic cooperation across departments for performance greater than the sum of its parts.

• AI Marketing: Tracks competitor strategies and social trends in real time, dynamically generating targeted content and pricing strategies using internal knowledge.

Efficient & Agile: Accelerates creative production and drives an integrated "strategy-content-pricing" engine for rapid market response.

• Online Knowledge Repository: A dedicated enterprise R&D knowledge base aggregating key data such as risk warnings, solutions, and technical documentation.

Significant Boost: Empowers faster troubleshooting and prevents redundant errors in R&D.

• Comprehensive Quality Control System: Embeds IPD checkpoints and technical reviews to govern key milestones; incorporates risk management for prevention, monitoring, and post-analysis.

Ultimate Goal: Ensure high-quality project delivery while minimizing potential risks.

After: Data-Driven Innovation Strategy Optimization

• Project Review: Compare project baselines with actual execution to deeply analyze quality, timeline, and cost performance.

Deeper Insights: Identify key factors that influence project success.

• Go-to-Market Tracking: Monitor GMV trends across e-commerce platforms, VOC on social media, and promotional campaign outcomes to pinpoint growth opportunities and risks, driving agile strategy iteration.

Advanced Capabilities: Fuel product iteration and innovation, providing a core foundation for the next-generation breakout product.

• Data Asset Management: Leverages delivery data and gate review points to auto-update master product data, creating a unified view with field supplementation and relationship validation.

Long-Term Value: Enables full-lifecycle product data management, enhancing both data quality and business utility.

The Cyberway Product Innovation Collaboration Platform is a powerful enabler for FMCG enterprises to enhance product innovation with AI, reduce waste, shorten R&D cycles, and create market bestsellers. From ideation to launch and ongoing optimization, the platform empowers excellence at every stage—allowing businesses to stand out in an intensely competitive landscape.

We look forward to partnering with more brands to explore new ways of innovation and co-create the next market blockbuster!

Website: https://www.cyberwayinc.com/?mts=4
Tel：4001680262 
Email：Marketing@cyberway.net.cn 

View original content:https://www.prnewswire.com/apac/news-releases/cyberway-product-innovation-platform-empowering-enterprise-innovation-processes-and-building-exceptional-product-strength-302487780.html

SOURCE Cyberway Information Technology Co., Ltd.

GUANGZHOU, China, June 22, 2025 /PRNewswire/ -- Cyberway Information Technology Co., Ltd. (hereinafter referred to as "Cyberway") is a leading digital marketing empowerment expert. Since its establishment, Cyberway has focused on the digital marketing landscape in the consumer goods industry, with business coverage across China and the Asia-Pacific region. Upholding a philosophy of long-term partnership, Cyberway has consistently collaborated with numerous Fortune 500 companies and globally renowned brands, jointly driving successful digital transformation and leading the new wave of intelligent marketing in the industry.

An Overview of Cyberway's Digital Marketing Services

Cyberway's service offerings are centered on the evolving needs of enterprise development and adhere to the "ALL IN ONE" philosophy. Unlike traditional single-product or single-service approaches, Cyberway delivers a full lifecycle of support—from industry expert consulting, full-chain marketing system implementation, and international-standard IT operations, to cutting-edge AI transformation and AI Agent deployment—tailored to various stages of digital maturity.

Cyber Insight: Industry-Expert Digital Marketing Consulting

As one of the few software vendors offering digital marketing consulting, Cyberway brings a deep understanding of FMCG business models and processes. Our consulting services include feasibility studies, holistic digital planning, and comprehensive project evaluation—helping enterprises gain panoramic insight, implement the right systems, and take the first step toward sustainable business growth.

Cyber 3A Model: The Industry's First Full-Chain Marketing Framework Integrating System, Data, and AI

With a core of modular configurability, the Cyber 3A Model seamlessly connects front-end applications and back-end data. By integrating cutting-edge AI technologies, Cyberway enables businesses to build comprehensive intelligent marketing platforms, reshaping end-to-end digital capabilities.

The model includes:

• Application Engine – Builds and connects full-chain marketing systems.
• Analytics Engine – Transforms data into strategic assets and drives decision intelligence.
• AI Engine (AI Middle Platform + AI Agent) – Accelerates real-world application of AI for enterprise use.

Integrated and Efficient  Digital Marketing Myetem Operations: Global Expertise, Local Execution

Aligned with the Cyber 3A integrated platform concept, Cyberway offers comprehensive solutions for both system and data operations. These services ensure stable performance in day-to-day operations while addressing challenges of traditional IT management.

With rich experience in overseas project delivery, Cyberway serves clients across Japan, South Korea, Singapore, Malaysia, Thailand, Australia, and New Zealand—offering deep insight into the unique demands of multinational FMCG enterprises.

AI Evolution: Enabling AI Transformation and Building AI Agents

Cyberway is committed to exploring AI technologies that enable enterprise digital transformation. In partnership with the School of Mathematics at Sun Yat-sen University, Cyberway co-established an AI research-industry-education innovation hub.

Through collaboration with Dify, one of the top three global AI development platforms, Cyberway delivers a mature AI Middle Platform. This enables FMCG companies to skip building AI infrastructure from scratch and instead focus on business needs, Agent objectives, and integration of private data and knowledge—laying the foundation for enterprise-level AI Agents.

From sales and marketing to R&D, IT, and operations, Cyberway empowers every function through "platform enablement + scenarios deep plowing" This approach transforms AI into real productivity, empowering business growth and accelerating enterprise-wide AI transformation.

Future Trends: Where Will FMCG Enterprises Focus Their Digital + Intelligent Transformation Efforts?

• Build an Enterprise-Level AI Middle Platform and Incubate AI Agents – Unlock Data Potential and Drive Smart Decisions & Personalized Experiences

With the maturation of AI technology, its application in the FMCG sector holds enormous potential. Building private AI Middle Platform and AI Agents ensures data security while delivering deep, scenario-based intelligence.

A high-efficiency, flexible, and user-friendly AI development platform enables enterprises to swiftly build, customize, and deploy AI Agents across business dimensions—forming a "Generative AI Application Factory" to power the enterprise AI brain.

AI Agents across the FMCG marketing value chain will become more than just tools—they will be intelligent assistants capable of autonomously performing complex tasks in various business scenarios, enhancing both operational efficiency and customer experience.

• Establish a Unified Master Data Management (MDM) Framework – Lay a Solid Data Foundation

In the journey toward digital and AI transformation, data is a core asset. However, data that is fragmented across systems, inconsistently formatted, and of varying quality often becomes a major obstacle.

Poor-quality data can lead to AI hallucinations, resulting in flawed outputs, misinformed decisions, and even wasted resources.

Cyberway's MDM approach — built on the principles of unified structure, language, and standards — establishes an enterprise-grade data governance framework that ensures consistency, uniqueness, and compliance at the root.

With end-to-end data governance that is standardized and AI-enabled, fragmented data is transformed into golden assets that fuel sustainable business growth.

• Build a Smart and Precision Marketing Expense Management Platform – Make Every Investment Count

Marketing accounts for a large portion of costs in the FMCG industry, yet traditional management methods often suffer from poor budget allocation, low transparency, and difficulty in tracking effectiveness.

Cyberway pioneered a three-stage marketing expense management framework—TPM (Transaction), TPE (Performance), and TPO (Optimization)—to address the varying needs of FMCG enterprises at different maturity levels.

The platform seamlessly integrates with systems such as MDM, SAP, SFA, BI, DMS, POS, and OA, ensuring unified data flows and laying a solid foundation for AI-enabled finance operations.

The platform is evolving with AI, embedding roles like Budget Planner, Campaign Mix Recommender, and Execution Optimizer—each powered by AI Agents—to serve targeted growth across brand, distributor, and retail layers.

• Build an Agile Product Innovation Collaboration Platform – Accelerate Product Launch and Market Fit

In a product-driven era, rapid iteration and precision innovation are essential for maintaining competitiveness in FMCG.

Traditional R&D processes are often slow, poorly coordinated, and disconnected from market feedback—hindering timely product launches.

Cyberway developed the first product innovation collaboration platform tailored to the FMCG sector, pioneering a "Three-Stream Parallel" model—Marketing Campaigns, Launch Readiness, and Product Development.

With end-to-end collaboration, standardized workflows, and data accumulation at its core, the platform leverages AI to make product innovation measurable, structured, and intelligent—boosting new product contribution rates.

As an official ISV partner of the Tmall Innovation Lab, Cyberway offers a wealth of resources to help brands identify emerging trends, streamline R&D, and ensure successful product launches.

Firmly rooted in the digital technology sector, Cyberway has established regional hubs in the Greater Bay Area, East China, and Southwest China, backed by a professional team of over 600 technical experts.

Driven by innovation and technological leadership, Cyberway continues to invest in R&D and deepen its innovation capabilities, consistently improving product quality and market competitiveness.

By staying aligned with AI and industry trends, Cyberway empowers enterprises to accelerate the growth of next-generation productivity and drive high-quality digital and intelligent transformation in the FMCG industry.

Website: https://www.cyberwayinc.com/?mts=3
Tel：4001680262
Email：Marketing@cyberway.net.cn 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cyberwaythe-common-choice-for-digital-transformation-of-fmcg-fortune-500-industries-302487776.html

SOURCE Cyberway Information Technology Co., Ltd.

DONGGUAN, China, June 22, 2025 /PRNewswire/ -- At the annual Huawei Developer Conference (HDC) 2025 Global Eco Summit and Sport Health Forum, Huawei unveiled its ambitious vision for the future of cross-border collaboration. Under the theme "Cross-border Integration," Huawei showcased its latest technological breakthroughs, joined by developers, partners and industry leaders sharing valuable insights. Through continuous innovation, forward-thinking solutions, and an open ecosystem, Huawei remains committed to delivering meaningful services and building a collaborative ecosystem connecting health, lifestyle and intelligent digital experiences across everyday life.

During HDC 2025, Huawei invited three key APAC eco-partners Grab, Siam Piwat and GCash to share collaboration insights.

Grab has partnered with Huawei since 2018, when its app launched on HUAWEI AppGallery offering ride-hailing and food delivery services. Chan Jian Hao, Regional Head - Global Mobility and OEM Partnerships at Grab, highlighted the recent integration of HarmonyOS Atomic Service improved user experience through installation-free features including booking rides with hassle-free logins with Huawei ID and seamless payment via Huawei Pay, real-time chat translation and post-trip support. Huawei also supported Grab with impactful promotional campaigns.

Tanavan Arkaleephan, Senior Director, Tourism Marketing Department at Siam Piwat, shared how Thailand's leading retail property developer attracts quality Chinese tourists through collaborations with Huawei's ecosystem, including SkyTone, Atomic Service and Petal Ads. Both parties jointly organised multiple engaging campaigns and APAC Multi-Country Travel Benefits program successfully attracted Chinese travellers to Thailand.

GCash, the Philippines' #1 Finance Super App and Largest Cashless Ecosystem, launched on HUAWEI AppGallery in 2018. Dani Gil Librojo, Payment Innovations Head at GCash, declared the collaboration has expanded with QR payments on Huawei wearables, benefiting 7 million smartwatch users to make seamless transactions. Huawei provided comprehensive support via device compatibility, security guidance, watch integration and multi-channel marketing.

HDC 2025 reinforced Huawei's leadership in shaping smart living through next-generation technology, intelligent software integration and strategic partnerships. Huawei is building a future centered on intelligent health, immersive content and seamless convenience, turning this vision into reality by enhancing users' daily life through its holistic ecosystem.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/huawei-and-apac-eco-partners-collaborate-to-enhance-intelligent-lifestyles-at-hdc-2025-302487737.html

SOURCE Huawei Mobile Services

GEN3 Evo iON Race Tires Triumph in Jakarta's Sweltering Round 12 Showdown

• Dan Ticktum conquers Jakarta's sweltering heat in a commanding drive at the Jakarta International E-Prix Circuit
• GEN3 Evo iON Race tires excel in grip, heat resistance, and stability across Jakarta's technically demanding layout and extreme track conditions
• The Season 11 title fight intensifies as Formula E leaves Asia behind and prepares for decisive final rounds in Berlin and London

JAKARTA, Indonesia, June 22, 2025 /PRNewswire/ -- Under Jakarta's unforgiving tropical heat, Hankook Tire & Technology (hereafter Hankook), a leading global tire company under the Hankook & Company Group, reinforced its performance leadership at the 2025 Jakarta E-Prix—Round 12 of the 2024/2025 ABB FIA Formula E World Championship (hereafter Formula E). After a one-season hiatus, Formula E roared back to action on the Jakarta International E-Prix Circuit (hereafter JIEC), a fiercely technical track set against the energetic backdrop of the Ancol waterfront.

Dan Ticktum secured a decisive victory—injecting new momentum into the escalating championship battle.  Oliver Rowland maintained his lead in the drivers' standings with 172 points, while TAG Heuer Porsche Formula E Team further solidified its dominance at the top of the teams' standings with 203 points.

The track, inspired by the flowing movements of the traditional Javanese Kuda Lumping dance, the 2.37km circuit pushed all 22 drivers to their limits with a mix of sweeping corners, tight technical sections, and scarce overtaking zones—made even more punishing by Jakarta's humidity and track surface temperatures exceeding 40°C.

Engineered exclusively by Hankook for Formula E, the GEN3 Evo iON Race tire proved pivotal in Jakarta's extreme conditions. Each team's two allocated sets delivered consistent grip, thermal resilience, and control—empowering drivers to push the limits through the circuit's most challenging sections without compromising performance or safety.

Maximilian Günther of DS Penske commented: "Jakarta's climate and circuit layout really test both the driver and the car to the edge. The GEN3 Evo iON Race tire handled the heat and surface complexity incredibly well. It gave me the confidence to attack and defend—even in the tightest corners. What's most impressive is how consistent the tire feels across conditions like this—something that clearly carries over into road tire technology too."

As Formula E concludes its Asia tour, the spotlight now shifts to the decisive final stretch of Season 11. Next up is the 2025 Hankook Berlin E-Prix, taking place on July 12 & 13—marking the penultimate double-header of the season and the final race to carry the Hankook race title sponsorship this season. As the championship race heats up, Hankook continues to lead the charge in electric motorsport innovation—delivering sustainable, high-performance tire solutions that extend beyond the racetrack and drive the future of global e-mobility.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/hankook-cements-its-tire-supremacy-at-the-2025-jakarta-e-prix-302487672.html

SOURCE Hankook Tire & Technology Co., Ltd.